Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 10/20 | 0.66 |
| ▸ | MEN1 | O00255 | 9/20 | 0.66 |
| ▸ | POLB | P06746 | 5/20 | 0.66 |
| ▸ | GAA | P10253 | 5/20 | 0.66 |
| ▸ | MAPT | P10636 | 7/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.50 |
| ▸ | LMNA | P02545 | 4/20 | 0.50 |
| ▸ | HTT | P42858 | 4/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.50 |
| ▸ | NPC1 | O15118 | 4/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.47 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.47 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.46 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19449736 | 0.85 | KMT2A (0.49) | KMT2AMEN1POLBGAAMAPT | |
| SCHEMBL17560970 | 0.80 | KMT2A (0.44) | KMT2AMEN1POLBGAAMAPT | |
| SCHEMBL17560967 | 0.80 | KMT2A (0.44) | KMT2AMEN1POLBGAAMAPT | |
| SCHEMBL15965638 | 0.75 | KMT2A (0.60) | KMT2AMEN1POLBGAAMAPT | |
| SCHEMBL17560842 | 0.73 | MEN1 (0.62) | KMT2AMEN1POLBGAAMAPT | |
| SCHEMBL17560848 | 0.73 | MEN1 (0.62) | KMT2AMEN1POLBGAAMAPT | |
| SCHEMBL11981834 | 0.72 | MEN1 (1.00) | KMT2AMEN1POLBGAAMAPT | |
| SCHEMBL1444473 | 0.72 | MEN1 (1.00) | KMT2AMEN1POLBGAAMAPT | |
| SCHEMBL23709452 | 0.71 | KMT2A (0.38) | KMT2AMEN1POLBGAAMAPT | |
| SCHEMBL21882611 | 0.71 | MEN1 (0.55) | KMT2AMEN1POLBGAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170291886-A1 | METHODS FOR TREATING PROTOZOAN INFECTIONS | NEOCULI PTY LTD (AU) | 2017-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170291886-A1 | METHODS FOR TREATING PROTOZOAN INFECTIONS | DPM1, ABCB11, PIGS | KMT2A 2912/4885MEN1 504/4885POLB 3872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.